Aardvark Therapeutics Reports Q2 Loss
Aardvark Therapeutics (NASDAQ:AARD), a clinical-stage biopharmaceutical company developing new treatments for rare and metabolic diseases, reported its financial results on August 13, 2025. The most notable aspect of the release was the continued lack of revenue, as the company stays pre-commercial, combined with a net loss per share of $(0.66) (GAAP). The net loss (GAAP) increased to $14.4 million driven mainly by sharply higher research and development costs. Overall, the period demonstrated progress across Aardvark’s clinical pipeline, but also highlighted a rapidly accelerating expense base. The company’s cash position at quarter-end was $141.8 million, which it expects will fund operations into 2027.
Source: Analyst estimates for the quarter provided by FactSet.
Aardvark Therapeutics develops therapies aimed at treating rare hyperphagic, or excessive hunger-related, conditions and challenging metabolic diseases. Its pipeline focuses on two main assets: ARD-101 for Prader-Willi syndrome (PWS) and hypothalamic obesity (HO), and ARD-201 for obesity, including situations where patients face weight rebound after stopping conventional obesity medications.
Source Fool.com
